Product image of Menquadfi (Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi) supplied by GNH India

Menquadfi

Active Ingredient:
Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi
Origin:
EU

Menquadfi (Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi)

Neisseria meningitidis serogroup C polysaccharide conjugated to tetanus toxoid, the active ingredient in Menquadfi, is a conjugate vaccine presented as a vaccine for intramuscular use. It prevents invasive disease caused by Neisseria meningitidis serogroup C in individuals at risk.

GNH India supplies Menquadfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sanofi Winthrop Industrie

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Menquadfi is a conjugate vaccine that targets meningococcal serogroup C disease.
  • Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C: provides immunity to reduce the risk of meningitis, septicemia and related severe infections.
  • Outbreak control in at‑risk populations: helps limit the spread of serogroup C during community or institutional outbreaks.
  • Travel protection for persons visiting endemic areas: lowers the chance of acquiring serogroup C infection while abroad.

How It Works

  • Menquadfi contains polysaccharide from Neisseria meningitidis serogroup C covalently linked to tetanus toxoid. The conjugation converts the polysaccharide into a T‑cell‑dependent antigen, prompting the immune system to produce high‑affinity IgG antibodies and memory B cells that specifically recognize the serogroup C capsule, thereby conferring active protection against infection.

Side Effects

Common Side Effects

  • Injection site pain, redness or swelling.
  • Mild fever or chills.
  • Headache.
  • Fatigue or malaise.
  • Muscle aches.
  • Nausea.

Serious or Rare Side Effects

  • Anaphylactic or severe allergic reaction.
  • Guillain‑Barré syndrome.
  • High‑grade fever.
  • Seizures.
  • Hypotension.
  • Severe local inflammation or abscess formation.

Precautions & Warnings

  • Menquadfi should be administered after careful assessment of the individual's health status.
  • Pregnancy: consult a healthcare professional; safety data are limited.
  • Breastfeeding: weigh potential benefits against unknown risks.
  • Allergy: avoid if there is a known hypersensitivity to any vaccine component.
  • Immunocompromised patients: may exhibit reduced antibody response; monitor effectiveness.
  • Fever monitoring: treat high fever promptly and report persistent symptoms.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Menquadfi may interact with other immunizations or immune‑modulating agents.

Major Interactions (Avoid)

  • Live vaccines: do not co‑administer within 4 weeks, as interference may reduce efficacy.
  • Immunoglobulin therapy: avoid within 3 months of vaccination, which can neutralize the antigen.

Moderate Interactions (Monitor Closely)

  • Antipyretics: may be used for post‑vaccination fever but could blunt the immune response if taken prophylactically.
  • Immunosuppressive drugs: may diminish antibody production; consider serologic testing.
  • Blood products: transfusion shortly after vaccination may affect immune priming.

Frequently Asked Questions

Menquadfi is a conjugate vaccine indicated for the prevention of invasive disease caused by Neisseria meningitidis serogroup C. It is used to protect individuals at risk of meningococcal meningitis, septicemia and related severe infections.

The vaccine contains polysaccharide from serogroup C linked to tetanus toxoid, converting the antigen into a T‑cell‑dependent form. This stimulates robust IgG antibody production and memory B‑cell formation, providing active immunity that specifically targets the serogroup C capsule.

The dosing schedule for Menquadfi is determined by the prescribing healthcare professional based on age, risk factors and local immunization guidelines. The prescriber will set the appropriate dose and interval.

Safety data for Menquadfi in pregnancy are limited, so it should be administered only if the potential benefit justifies the potential risk. Breastfeeding mothers should discuss the vaccine with their clinician to weigh benefits against any unknown risks.

To order Menquadfi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and import documentation.

Menquadfi is a serogroup C‑specific conjugate vaccine, whereas some alternatives cover multiple serogroups (A, C, W, Y, or B). The conjugate format offers a T‑cell‑dependent response, leading to stronger and longer‑lasting immunity compared with plain polysaccharide vaccines.

Menquadfi must be stored at 2 °C to 8 °C. Keep it refrigerated, protect from light, and avoid freezing or shaking the vial. Follow the cold‑chain protocol during transport and handling to maintain vaccine potency.

Menquadfi is given by intramuscular injection, typically into the deltoid muscle of the upper arm. The injection should be performed by a qualified healthcare professional using aseptic technique.

Serious adverse events, although rare, can include anaphylaxis, Guillain‑Barré syndrome, high‑grade fever, seizures, and severe local reactions. Any signs of a severe allergic response or neurological symptoms should be reported to a medical professional immediately.

Individuals with a known severe allergy to any component of Menquadfi, including the tetanus toxoid carrier, should not receive the vaccine. Those with a history of severe allergic reactions to previous meningococcal vaccines should also avoid it unless cleared by a specialist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT